BridgeBio Oncology Therapeutics
Develops small-molecule therapies for RAS- and PI3K-driven malignancies.
$8.91
After-hours close+0.19 (+2.18%)
At close$8.72(−5.01%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.56 | — | — |
| Aug 2026 | −$0.57 | −$0.71 | −24.8% |
| Jun 2026 | −$0.51 | −$0.53 | −2.8% |
| May 2026 | −$0.51 | −$0.53 | −2.8% |
| Mar 2026 | −$0.63 | −$0.48 | +24.2% |
The latest year is open to everyone — the 9 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Dec 2023 | |||
| Dec 2022 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.56 | — | — | — | — | — |
| Aug 11, 2026 | −$0.57 | −$0.71 | −24.8% | — | — | — |
| Jun 4, 2026 | −$0.51 | −$0.53 | −2.8% | — | — | — |
| May 12, 2026 | −$0.51 | −$0.53 | −2.8% | — | — | — |
| Mar 5, 2026 | −$0.63 | −$0.48 | +24.2% | — | — | — |
The latest year is open to everyone — the 9 quarters behind it read with an account. Sign in | ||||||
| Nov 12, 2025 | ||||||
| Aug 1, 2025 | ||||||
| May 15, 2025 | ||||||
| Mar 11, 2025 | ||||||
| Nov 14, 2024 | ||||||
| Aug 14, 2024 | ||||||
| May 15, 2024 | ||||||
| Dec 31, 2023 | ||||||
| Dec 31, 2022 | ||||||